HKPD (Cellyan Biotechnology Co) Total Stockholders Equity: $9.58 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKPD Cellyan Biotechnology Co Ltd HKPD
18 GF Score
Price $0.37
! 3 Warning Signs
View Full Analysis

What is Cellyan Biotechnology Co Total Stockholders Equity?

Cellyan Biotechnology Co HKPD -8.98% 18 Total Stockholders Equity is $9.58 Mil as of Mar. 2026. GuruFocus rates HKPD with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Cellyan Biotechnology Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $9.58 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cellyan Biotechnology Co's Book Value per Share for the quarter that ended in Mar. 2026 was $0.41. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cellyan Biotechnology Co's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.13.

Cellyan Biotechnology Co  (NAS:HKPD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cellyan Biotechnology Co's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(9.583-0)/23.500
=0.41

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cellyan Biotechnology Co's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.193 + 0.065) / 9.583
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellyan Biotechnology Co Total Stockholders Equity Related Terms

Cellyan Biotechnology Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cellyan Biotechnology Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellyan Biotechnology Co Total Stockholders Equity Chart

Cellyan Biotechnology Co Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
0.59 4.25 4.99 9.58

Cellyan Biotechnology Co Semi-Annual Data
Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial 4.25 5.35 4.99 5.14 9.58
HKPD
18GF Score
Cellyan Biotechnology Co Ltd HKPD
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $9.58 Mil mean?
Cellyan Biotechnology Co (HKPD) has a Total Stockholders Equity of $9.58 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cellyan Biotechnology Co and its competitors.
Is Cellyan Biotechnology Co's Total Stockholders Equity too high?
Cellyan Biotechnology Co's current Total Stockholders Equity is $9.58 Mil. Overall, Cellyan Biotechnology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Total Stockholders Equity compare to MEDS and COSM?
Cellyan Biotechnology Co's Total Stockholders Equity of $9.58 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Distribution company?
A good Total Stockholders Equity depends on the Medical Distribution industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current Total Stockholders Equity is $9.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Total Stockholders Equity of $9.58 Mil. The current Total Stockholders Equity is $9.58 Mil. Cellyan Biotechnology Co's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Total Stockholders Equity is $9.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellyan Biotechnology Co Business Description

Address 13 Ko Fai Road, Room B1, 5th Floor, Well Town Industrial Building, Yau Tong, Kowloon, Hong Kong, HKG
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
18GF Score

Get the complete analysis for HKPD

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price